Welcome to our dedicated page for Charles Riv Labs Intl SEC filings (Ticker: CRL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Charles River Laboratories International, Inc. (NYSE: CRL) provides direct access to the company’s regulatory disclosures, along with AI-powered tools that help interpret complex documents. Charles River operates in research and development in biotechnology within the professional, scientific, and technical services sector, and its filings offer detailed insight into how it manages growth, risk, governance, and capital allocation.
Investors can review annual reports on Form 10-K and quarterly reports on Form 10-Q to understand segment performance across Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions. These reports typically discuss demand trends, restructuring initiatives, portfolio refinement, and the use of non-GAAP measures that exclude items such as acquisition-related amortization, restructuring costs, and certain legal expenses. AI summaries can highlight key sections, such as discussions of organic revenue, operating margins, and the rationale for using non-GAAP metrics.
Current reports on Form 8-K are especially important for tracking material events at Charles River. Recent 8-K filings have described planned acquisitions of K.F. (Cambodia) Ltd. and PathoQuest SAS, updates on Discovery and Safety Assessment demand indicators, the outcome of an SEC Division of Enforcement investigation into non-human primate sourcing, strategic review outcomes, and leadership changes including CEO succession and executive compensation arrangements. AI analysis can surface these items, explain their context, and point to related risk factor or management discussion sections in periodic reports.
Users interested in governance and executive arrangements can examine 8-K and 8-K/A filings detailing appointments, resignations, and compensation terms for senior leaders, as well as board decisions on stock repurchase authorizations and change-in-control agreements. While insider trading activity is disclosed separately on Forms 3, 4, and 5, this page is designed to link related ownership and compensation information to the broader narrative in 10-Ks, 10-Qs, and 8-Ks.
All filings are updated in near real time from the SEC’s EDGAR system. AI-powered summaries help readers quickly identify the main points of lengthy documents, such as how acquisitions like K.F. (Cambodia) Ltd. and PathoQuest SAS are expected to affect Discovery and Safety Assessment or Biologics Testing operations, or how restructuring and portfolio divestitures relate to the company’s focus on core scientific capabilities and long-term shareholder value.
Charles River Laboratories International, Inc. is asking shareholders to vote at its May 5, 2026 annual meeting on four main items: electing twelve directors, approving a new long-term incentive plan, holding an advisory vote on executive pay, and ratifying PricewaterhouseCoopers LLP as auditor for 2026.
The proxy highlights a leadership transition in which long-time Chair and CEO James C. Foster will retire from those roles, with Chief Operating Officer Birgit Girshick becoming Chief Executive Officer and joining the Board, while Foster remains a non-executive director. The company seeks approval of a 2026 Long-Term Incentive Plan authorizing up to 4,825,000 shares of common stock for equity awards to support its compensation and retention strategy. It also notes strong prior say-on-pay support and describes governance features such as majority voting, proxy access, board evaluations, independent committees, and a clawback policy.
Charles River Laboratories International, Inc. Schedule 13G/A: The Vanguard Group reports 0 shares beneficially owned and 0% of common stock following an internal realignment. The filing explains certain Vanguard subsidiaries will report holdings separately in reliance on SEC Release No. 34-39538. The amendment is signed by the Head of Global Fund Administration on 03/26/2026.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. executive Birgit Girshick, Corporate Executive VP & COO, reported an indirect bona fide gift of 328 shares of common stock on March 4, 2026. The gifted shares were held indirectly through a revocable trust and transferred at a reported price of $0.00 per share, reflecting a non-sale disposition.
After this gift, indirect holdings through the revocable trust were reported as 40,417 shares of common stock, while direct holdings were reported as 31,638 shares. A footnote explains that the indirect total includes shares previously reported as directly held, which are now correctly classified as indirectly held.
FOSTER JAMES C reported acquisition or exercise transactions in this Form 4 filing.
Charles River Laboratories International Chairman, President and CEO James C. Foster received an equity award tied to the company’s common stock. He was granted 16,796 shares at a reference price of $178.61 per share, increasing his directly held stake to 279,693 shares.
According to a footnote, 100% of the unvested restricted stock units from this grant vest on March 2, 2028. Additional common stock is held indirectly through GRATs, trusts and a spouse account, and a separate footnote notes an exempt transfer of 9,220 shares from a 2025 GRAT account to direct holdings.
Charles River Laboratories International executive Joseph W. LaPlume bought 25 shares of common stock in an open-market purchase at $174.54 per share on March 3, 2026. Following this transaction, his directly held stake increased to 27,448 shares.
Charles River Laboratories plans two sizable divestitures and has revised its 2026 outlook to reflect the impact. The company signed a definitive agreement to sell its CDMO and Cell Solutions businesses to GI Partners, primarily for future, contingent performance-based payments, after those units generated $143 million of revenue in 2025. It also agreed to sell certain European Discovery Services assets to IQVIA for about $145 million in cash plus up to $10 million more.
Together, the planned divestitures are expected to reduce 2026 reported revenue by slightly more than 5%, shifting guidance to a reported decline of 5.0% to 3.5%. At the same time, management expects at least 100 basis points of incremental non-GAAP operating margin improvement in 2026 and about $0.10 of non-GAAP EPS accretion for the partial year, raising its non-GAAP EPS guidance range to $10.80–$11.30.
Charles River Laboratories International, Inc. appointed Glenn Coleman as Corporate Executive Vice President and Chief Financial Officer. He is expected to start on April 6, 2026, succeeding interim CFO Michael G. Knell, who will continue as Corporate Senior Vice President and Chief Accounting Officer.
Mr. Coleman, 58, brings more than 30 years of financial and operational experience, including senior roles in the healthcare sector. He most recently served as Chief Financial Officer and Chief Administrative Officer of Premier, Inc., and previously held CFO and operational leadership positions at DENTSPLY SIRONA Inc. and Integra Life Sciences Holdings Corporation.
Charles River Laboratories International, Inc. outlines its 2025 results and strategy as a global non‑clinical drug development partner. The company generated $4.0 billion in revenue, with Discovery and Safety Assessment contributing 59.8%, Research Models and Services 21.1%, and Manufacturing Solutions 19.1%.
The business spans over 120 sites in more than 20 countries and serves large pharma, biotech, academia, and government clients, with no single client above 4% of total revenue. Charles River is optimizing its footprint by planning to close or consolidate about 12 sites and divest non‑core assets representing roughly 7% of 2025 revenue.
The company ended 2025 with backlogs of approximately $1.9 billion in Discovery and Safety Assessment, $640 million in Research Models and Services, and $123 million in Manufacturing. It employed about 19,700 people and emphasizes animal welfare, new approach methodologies, and digital tools to support clients’ drug discovery and development.
Charles River Laboratories International, Inc. reported slightly lower 2025 results and issued a cautious 2026 outlook. Fourth-quarter 2025 revenue was $994.2 million, down 0.8% year over year, with organic revenue down 2.6% as softness in Discovery and Safety Assessment and Manufacturing offset growth in some research model services.
The company posted a GAAP net loss of $276.6 million for the quarter, or $(5.62) per share, driven largely by $211.0 million of intangible asset impairments and $165.0 million of goodwill impairment in its Biologics Solutions and Cell Solutions operations. On a non-GAAP basis, Q4 diluted EPS was $2.39, down from $2.66. For full-year 2025, revenue was $4.02 billion, down 0.9%, with GAAP diluted loss per share of $(2.91) versus earnings of $0.20 in 2024, while non-GAAP diluted EPS slipped to $10.28 from $10.32.
Management highlighted improved late-2025 bookings in Discovery and Safety Assessment and issued 2026 guidance calling for reported revenue growth of at least flat to 1.5%, organic revenue ranging from a 1.0% decline to flat, and non-GAAP EPS between $10.70 and $11.20, reflecting expected cost savings, contribution from the K.F. (Cambodia) Ltd. asset acquisition, and a lower tax rate.